Enfortumab vedotin 20/30 mg is an innovative treatment for advanced urothelial carcinoma. Targeting the Nectin-4 protein, it delivers a cytotoxic agent directly to cancer cells, reducing toxicity to healthy tissues. Available in India, Enfortumab vedotin 20/30 mg in India has shown improved survival rates and offers a promising treatment option for patients who have undergone chemotherapy and immunotherapy. For more information click on this link-:https://www.impomedhealthcare.com